Search Results for "Xarelto Vs Pradaxa"

02:06 EDT 24th October 2017 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Pradaxa Meets Primary Endpoint and Shows Favorable New Safety Data

NewsRE-DUAL PCI results offer favorable new safety data on Pradaxa. Large safety study compared dual therapy with Pradaxa to triple therapy with warfarin in people who have undergone percutaneous coro...

Newer Blood Thinners May Not Bring Higher Bleeding Risk

WEDNESDAY, Oct. 18, 2017 -- New anti-clotting drugs -- like Xarelto, Pradaxa and Eliquis -- aren't linked with a higher risk of bleeding than the older drug warfarin, a new study finds. Many patients ...

CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics

Monday, September 18th 2017 at 7:08am UTC The CHMP of the EMA has issued a positive opinion for an update of the Summary of Product Characteristics (SmPC) for Pradaxa® (dabigatran etexilate) The CHMP...

Bayer reports successful trial of Xarelto drug

Bayer AG on Sunday said that results of its phase III study of the blood thinner Xarelto showed that it lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chro...

Xarelto significantly reduced major CV events in stable CAD/PAD patients

Results from the pivotal Phase III COMPASS study found that the Xarelto (rivaroxaban) vascular dose (2.5mg…

Bayer and J&J Win Third Xarelto Case

Germany’s Bayer and Johnson & Johnson (J&J) of the US have won the third of three lawsuits involving bleeding risks of the blockbuster blood thinner Xarelto, which was developed and prod...

Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement

RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy Both Pradaxa® doses tested in RE-DUAL PCI™ ha...

Priority review status granted to J&J for lower dose of Xarelto

Johnson & Johnson unit Janssen Research & Development's supplemental new drug application for a 10-mg daily dose of Xarelto,  -More- 

Matching PubMed Articles


Search Whole site using Google

Quick Search
Advertisement Advertisement